BLVRA catalyzes the reduction of biliverdin IXα to bilirubin, the final step in heme catabolism. The enzyme uses NADH or NADPH as a cofactor, with NADPH serving as the probable physiological substrate. Beyond its canonical enzymatic role, BLVRA possesses a protein kinase domain activated by biliverdin binding, which engages mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways linked to cell growth and survival 1. BLVRA also functions as a transcription factor regulating immune-modulatory gene expression 1. Genetic variants in BLVRA are associated with neonatal hyperbilirubinemia in Chinese Han populations; carriers of the G-allele at rs699512 show reduced disease risk 2. BLVRA expression is elevated in glioblastoma tissues and cell lines, and correlates with poor prognosis; knockdown suppresses proliferation and induces oxidative stress-mediated apoptosis 3. Similarly, BLVRA upregulation in hepatocellular carcinoma promotes cell proliferation and invasion via Wnt/β-catenin pathway activation 4. A fusion protein delivering BLVRA into dopaminergic neurons protected against oxidative stress-induced cell death in Parkinson's disease models 5, suggesting therapeutic potential for neurodegenerative conditions. The antioxidant and signaling properties of bilirubin generated by BLVRA support broader physiological roles in preventing metabolic and cardiovascular disease 6.